指南与共识支持与姑息治疗

ASCO-FOCR工作组:现代化临床试验入组标准建议

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group.
指南 / 共识 · J Clin Oncol · 2017-10-02

ASCO与癌症研究之友成立多学科工作组,分析现有入组标准并达成共识,建议在肾脏、肝脏、心脏功能及血液病相关实验室异常和功能状态方面扩大入组,以增加试验人群多样性和代表性。

要点

  • 若肾毒性和清除率非直接治疗关注点,肌酐清除率>30 mL/min患者应入组。
  • 轻中度肝功能障碍患者在非临床和临床数据总体表明安全时可考虑入组。
  • 应结合射血分数与研究者对心衰风险评估确定入组资格。

核心结论

  • 扩大脏器功能障碍、既往或并发恶性肿瘤及合并症患者的入组将增加试验患者数量和多样性,形成更合适的患者人群。

研究设计与样本

  • ASCO与Friends of Cancer Research成立多学科工作组,分析现有入组标准、进行原始数据分析、讨论安全性及潜在障碍并达成共识建议。

主要发现

  • 若肾毒性和清除率非直接治疗相关关注点,肌酐清除率>30 mL/min的患者应入组试验。
  • 当现有非临床和临床数据总体表明安全时,轻中度肝功能障碍患者可能可以入组。
  • 射血分数值应结合研究者对患者心衰风险的评估来确定入组资格。
  • 因血液病导致实验室参数超出正常范围的患者应入组试验。
  • 应纳入患者功能状态测量以更好评估健壮与衰弱患者。

关键数值与推荐

  • 肌酐清除率>30 mL/min的患者应入组,前提是肾毒性和清除率非直接治疗相关关注点。
  • 轻中度肝功能障碍患者在现有非临床和临床数据总体表明安全时可考虑入组。
  • 射血分数值应与研究者对患者心衰风险的评估结合用于入组资格判定。

临床怎么用

  • 在试验入组时,若肾毒性和清除率非直接治疗关注点,可纳入肌酐清除率>30 mL/min患者。
  • 轻中度肝功能障碍患者在数据总体表明安全时可考虑入组。
  • 使用射血分数结合研究者对心衰风险的评估判断入组资格。
  • 因血液病导致实验室参数异常的患者应纳入试验。
  • 纳入功能状态测量以更好区分健壮与衰弱患者。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Patients with organ dysfunction, prior or concurrent malignancies, and comorbidities are often excluded from clinical trials. Excluding patients on the basis of these factors results in clinical trial participants who are healthier and younger than the overall population of patients with cancer. Methods ASCO and Friends of Cancer Research established a multidisciplinary working group that included experts in trial design and conduct to examine how eligibility criteria could be more inclusive. The group analyzed current eligibility criteria; conducted original data analysis; considered safety concerns, potential benefits, research, and potential hurdles of this approach through discussion; and reached consensus on recommendations regarding updated eligibility criteria that prioritize inclusiveness without compromising patient safety. Results If renal toxicity and clearance are not of direct treatment-related concern, then patients with lower creatinine clearance values of > 30 mL/min should be included in trials. Inclusion of patients with mild to moderate hepatic dysfunction may be possible when the totality of the available nonclinical and clinical data indicates that inclusion is safe. Ejection fraction values should be used with investigator assessment of a patient's risk for heart failure to determine eligibility. Patients with laboratory parameters out of normal range as a result of hematologic disease should be included in trials. Measures of patient functional status should be included in trials to better assess fit versus frail patients. Conclusion Expanding inclusion of these patients will increase the number and diversity of patients in clinical trials and result in a more appropriate population of patients.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lichtman SM, Harvey RD, Damiette Smit MA, et al. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group. J Clin Oncol. 2017. PMID: 28968172. doi:10.1200/JCO.2017.74.4102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。